NCT06311578View on ClinicalTrials.gov

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

April 10, 2024

Primary Completion Date

November 8, 2028

Study Completion Date

August 26, 2032

Conditions
Advanced Solid Tumors
Interventions
DRUG

JNJ-87704916

JNJ-87704916 will be administered as an intratumoral injection.

DRUG

Cetrelimab

Cetrelimab will be administered.

Trial Locations (8)

10016

RECRUITING

NYU Langone Health, New York

15232

RECRUITING

UPMC Cancer Centers, Pittsburgh

19111

RECRUITING

Fox Chase Cancer Center, Philadelphia

28040

RECRUITING

Hosp Univ Fund Jimenez Diaz, Madrid

28050

RECRUITING

Hosp Univ Hm Sanchinarro, Madrid

77030

RECRUITING

MD Anderson Cancer Center, Houston

94805

RECRUITING

Gustave Roussy, Villejuif

08035

RECRUITING

Hosp Univ Vall D Hebron, Barcelona

All Listed Sponsors
lead

Johnson & Johnson Enterprise Innovation Inc.

INDUSTRY